Innoviva (INVA) vs uniQure N.V. (QURE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Innoviva (INVA) has outperformed uniQure N.V. (QURE) over the past year, gaining 20.1% versus a loss of 62.4%. Over five years, INVA leads with a +25.6% price change compared with -25.0% for QURE. uniQure N.V. is the larger company by market cap ($1.57 billion vs $1.53 billion), about 1.0 times the size, while Innoviva is growing revenue faster (+14.7% vs -40.6%).
Innoviva converts more of its revenue into profit, with a net margin of 65.9% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INVA | QURE |
|---|---|---|
| Share price | $21.21 | $22.59 |
| Market cap | $1.53B | $1.57B |
| 1-day change | +1.63% | +0.22% |
| YTD return | +4.40% | -5.81% |
| 1-year return | +20.15% | -62.41% |
| 5-year return | +25.65% | -25.02% |
| P/E ratio (TTM) | 4.96 | — |
| Forward P/E | 9.60 | — |
| EPS (TTM) | $4.28 | $-4.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $411.33M | $16.10M |
| Revenue growth (YoY) | +14.67% | -40.64% |
| Net income (latest FY) | $271.17M | $-198.97M |
| Gross margin | 74.80% | 89.53% |
| Operating margin | 39.81% | -1151.38% |
| Net margin | 65.92% | -1236.00% |
| 52-week high | $25.15 | $71.50 |
| 52-week low | $16.52 | $8.73 |
| Distance from 52-week high | -15.67% | -68.41% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +65.02% | +175.92% |
| Average volume | 819.03K | 1.97M |
| Shares outstanding | 72.25M | 69.37M |
| Employees | 159 | 221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INVA has outperformed QURE by 82.6 percentage points over the past year.
- Innoviva is more profitable, keeping 65.9 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- Innoviva grew revenue faster in its latest fiscal year (+14.67% vs -40.64%).
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
INVA vs QURE FAQ
Which is bigger, Innoviva or uniQure N.V.?
uniQure N.V. (QURE) is larger, with a market capitalization of $1.57B compared with $1.53B for Innoviva (INVA).
Which stock has performed better over the past year, INVA or QURE?
INVA returned +20.15% over the past 12 months, compared with -62.41% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are Innoviva and uniQure N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.